No correlation between progression-free survival and Sec62 expression was detected when including the whole cohort, the cohort of patients with ovarian cancer or the cohort of patients with borderline tumors of the ovary respectively (whole cohort p = 0.15; ovarian cancer p = 0.13; borderline tumors of the ovary p = 0.74) (Table 4; Figure 3). Here, SEC62 is linked to ovarian cancer.